SEngine Precision Medicine raises $5.1m in a Series A investment round to further develop its 3D tumor organoid diagnostic and drug discovery platform.
SEngine Precision Medicine and Atomwise recently announced a new joint venture through which the companies aim to ‘speed and streamline’ new drug discovery, says CEO.